蛋白激酶G是可溶性鸟苷酸环化酶激动剂抗纤维化效应的必需下游介质
本研究探讨蛋白激酶G(PKG)作为可溶性鸟苷酸环化酶(sGC)-环磷酸鸟苷(cGMP)下游介质在系统性硬化症(SSc)中的作用。PKG1和2双敲除小鼠接受博来霉素并用sGC激动剂BAY 41-2272处理,成纤维细胞用BAY 41-2272及PKG抑制剂KT 5823处理。结果显示PKG是sGC激动剂抗纤维化效应的必需介质,通过干扰非经典TGFβ信号实现。
要点
- PKG1和2在SSc中以TGFβ1依赖方式上调,为代偿sGC-cGMP-PKG通路信号降低。
- 抑制或敲除PKG1和2可消除sGC激动剂对成纤维细胞活化的抑制效应,且不依赖SMAD而依赖ERK。
- 在PKG1和2敲除小鼠体内,sGC激动剂不能预防博来霉素诱导的纤维化。
核心结论
- PKG是sGC激动剂抗纤维化效应的必需介质,其通过干扰非经典TGFβ信号发挥作用。
- TGFβ1通过抑制sGC-cGMP-PKG信号促进其促纤维化效应,sGC激动剂通过抑制TGFβ1诱导的ERK磷酸化发挥抗纤维化效应。
研究设计与样本
- 研究采用PKG1和2联合敲除小鼠,以博来霉素诱导模型并给予sGC激动剂BAY 41-2272处理。
- 体外对成纤维细胞给予BAY 41-2272及PKG抑制剂KT 5823处理。
主要发现
- PKG1和2在SSc中以TGFβ1依赖方式上调,为代偿sGC-cGMP-PKG通路信号降低。
- 抑制或敲除PKG1和2可消除sGC刺激对成纤维细胞活化的抑制效应,且不依赖SMAD而依赖细胞外信号调节激酶(ERK)。
- 在PKG1和2敲除小鼠体内,sGC刺激不能预防博来霉素诱导的纤维化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Stimulators of soluble guanylate cyclase (sGC) are currently investigated in clinical trials for the treatment of fibrosis in systemic sclerosis (SSc). In this study, we aim to investigate the role of protein kinases G (PKG) as downstream mediators of sGC-cyclic guanosine monophosphate (cGMP) in SSc. METHODS: Mice with combined knockout of PKG1 and 2 were challenged with bleomycin and treated with the sGC stimulator BAY 41-2272. Fibroblasts were treated with BAY 41-2272 and with the PKG inhibitor KT 5823. RESULTS: PKG1 and 2 are upregulated in SSc in a transforming growth factor-β1 (TGFβ1)-dependent manner, as an attempt to compensate for the decreased signalling through the sGC-cGMP-PKG pathway. Inhibition or knockout of PKG1 and 2 abrogates the inhibitory effects of sGC stimulation on fibroblast activation in a SMAD-independent, but extracellular signal-regulated kinase (ERK)-dependent manner. In vivo, sGC stimulation fails to prevent bleomycin-induced fibrosis in PKG1 and 2 knockout mice. CONCLUSIONS: Our data provide evidence that PKGs are essential mediators of the antifibrotic effects of sGC stimulators through interfering with non-canonical TGFβ signalling. TGFβ1 promotes its profibrotic effects through inhibition of sGC-cGMP-PKG signalling, sGC stimulation exerts its antifibrotic effects by inhibition of TGFβ1-induced ERK phosphorylation.
引用
- Matei AE, Beyer C, Györfi AH, et al. Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann Rheum Dis. 2018. PMID: 29311148. doi:10.1136/annrheumdis-2017-212489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。